For patients with recurrence of advanced NSCLC with inaccessible tissues, CEA expression can be used as a referential indicator to predict therapeutic efficacy of EGFR tyrosine kinase inhibitors [23]. Here, CEACAM5 is linked to non-small cell lung carcinoma.